The over-all therapeutic usefulness of glybenclamide, a new derivative of the hypoglycemie sulfonylureas, was studied in 116 diabetics of all types.

Glybenclamide appears to be a very potent hypoglycemie drug without serious toxicity on short-term trial but its clinical spectrum is similar to that of previously known hypoglycemie sulfonamides.

This content is only available via PDF.